Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Orexigen Therapeutics, Inc
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects, 18 to 60 years of age (inclusive)
Outpatients with a current diagnosis of OCD that have received previous therapy
Negative serum pregnancy test as screening in women of child-bearing potential
If a woman of child-bearing potential, must agreed to use an acceptable and effective form of contraception
No clinically significant abnormality on electrocardiogram (ECG)
No clinically significant laboratory abnormality at screening
Negative urine drug screen
Must be considered reliable and possess a level of understanding that enables the subject to provide written informed consent and to comply with protocol procedures and schedule
You may not be if
Diagnosis of substance dependence
Diagnosis of substance abuse (except for nicotine and caffeine)
Serious or unstable medical illnesses
Lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, anorexia nervosa, Pervasive Developmental Disorder (PDD), Asperger's Syndrome or the presence of antisocial or borderline personality disorder
Diagnosis of tic disorder or Tourette's Syndrome
Subjects diagnosed with impulse control disorder
Known sensitivity or allergic reaction to either naltrexone or fluoxetine
Any condition which in the opinion of the investigator or Sponsor makes the subject unsuitable for inclusion in the study
Immediate family of investigators, study personnel or Sponsor representatives
Clareo Health | Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
